Cetya has a portfolio of over 30 analogs of largazole for evaluation in a multitude of therapeutic indications. The largazole scaffold also lends itself to further modification to develop optimized analogs suited to a particular clinical indication.
Much of the further research at Cetya will be devoted to the study of the structure/activity relationships against a specific biological readout predictive of efficacy in a certain clinical indication.
Additionally, Cetya has the capability of targeting any of its analogs to any cell-type of interest for treatment of a particular clinical indication. Targeting is the classic approach to reducing systemic toxicity, as evidenced by the development of monoclonal antibodies or alternative formulation strategies such as nanoparticle delivery systems. Cetya will incorporate this targeting function where necessary to shift the risk benefit ratio in the patient’s favor.